The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•17 April 2026•

1 min read

Runway Growth Closes SWK Acquisition as Nurix Therapeutics Reports Q1 Results

Canadian flag, a plasma bag, and "GRIFOLS" text on an orange background with medical equipment, microscopes, and vials.

Key Facts

1Runway Growth Finance Corp. completed the acquisition of SWK Holdings Corporation to expand its healthcare and life sciences exposure.

Runway Growth Finance Corp. has officially completed its acquisition of SWK Holdings Corporation, a move designed to significantly expand its footprint in the healthcare and life sciences sectors. During the first quarter of 2026, Runway Growth deployed $17.6 million in capital across four investments involving both new and existing portfolio companies. Simultaneously, Nurix Therapeutics reported its Q1 2026 financial results, highlighting clinical progress in its Phase 2 DAYBreak trial for bexobrutine in treating chronic lymphocytic leukemia. These corporate milestones underscore a period of strategic scaling for Runway Growth and clinical advancement for Nurix. Market participants are closely monitoring the integration of SWK Holdings and the potential for accelerated clinical approvals for Nurix's pipeline. Overall, these updates signal a constructive outlook for the involved entities within the venture debt and biotech landscapes.